Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 901 - 925 of 14506 in total
Reslizumab is a humanized interleukin-5 (IL-5) antagonist monoclonal antibody (IgG4 kappa) that is produced by recombinant DNA technology in murine myeloma non-secreting 0 (NS0) cells. IL-5 is a pro-inflammatory cytokine that is responsible for the growth and differentiation, recruitment, activation, and survival of eosinophils [FDA Label]. Elevated levels of eosinophils...
Approved
Investigational
Matched Description: … and promote programmed cell death [A31578]. ... , activation, and survival of eosinophils [FDA Label]. ... for recurrent exacerbation and asthma-related hospitalizations [A31579]. …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Retinal vascular diseases (RVDs) such as diabetic macular edema (DME), age-related macular degeneration (AMD), and retinal vein occlusion (RVO) are typically caused by retinal ischemia and subsequent neovascularization (NV).[A225985, A225990, A225995] Vascular endothelial growth factor A (VEGF-A) is a well-known mediator of retinal NV, and many currently approved RVD therapies...
Approved
Investigational
Matched Description: … vascular diseases (RVDs) such as diabetic macular edema (DME), age-related macular degeneration (AMD), and ... retinal vein occlusion (RVO) are typically caused by retinal ischemia and subsequent neovascularization ... many currently approved RVD therapies such as [aflibercept] and [ranibizumab] solely target VEGF-A. …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, fallopian tube, or...
Approved
Investigational
Matched Description: … [L43277] Niraparib is selective towards PARP-1 and PARP-2. ... [L43277] Niraparib was approved by the European Commission on November 16, 2017 [L43742] and by Health …
Matched Categories: … niraparib and abiraterone ... Antineoplastic and Immunomodulating Agents …
Antiarrhythmic agent pharmacologically similar to lidocaine. It may have some anticonvulsant properties.
Approved
Investigational
A synthetic broad-spectrum fluoroquinolone antibacterial agent active against most gram-negative and gram-positive bacteria.
Approved
Matched Description: … A synthetic broad-spectrum fluoroquinolone antibacterial agent active against most gram-negative and
Matched Categories: … Metabolic Side Effects of Drugs and Substances …
Paroxetine is a selective serotonin reuptake inhibitor (SSRI) drug commonly known as Paxil. It has a variety of uses, including the treatment of anxiety disorders, major depression, posttraumatic stress disorder, and symptoms of menopause, among others. It was approved by the FDA in the early 1990s and marketed by SmithKline...
Approved
Investigational
Matched Description: … of serotonin reuptake and has little effect on other neurotransmitters. ... [T653] It was approved by the FDA in the early 1990s and marketed by SmithKline Beecham. ... uses, including the treatment of anxiety disorders, major depression, posttraumatic stress disorder, and
Flunarizine is a selective calcium entry blocker with calmodulin binding properties and histamine H1 blocking activity. It is effective in the prophylaxis of migraine, occlusive peripheral vascular disease, vertigo of central and peripheral origin, and as an adjuvant in the therapy of epilepsy.
Approved
Matched Description: … peripheral origin, and as an adjuvant in the therapy of epilepsy. ... Flunarizine is a selective calcium entry blocker with calmodulin binding properties and histamine H1 ... effective in the prophylaxis of migraine, occlusive peripheral vascular disease, vertigo of central and
Matched Categories: … Calcium-Regulating Hormones and Agents …
Flutemetamol (18F) is a PET scanning radiopharmaceutical containing the radionuclide fluorine-18. It is indicated for Positron Emission Tomography (PET) imaging of the brain to estimate β amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's disease (AD) or other causes of cognitive decline.
Approved
Investigational
Matched Categories: … Indicators and Reagents …
Ezogabine (D23129) is a close structural analog of the centrally acting analgesic flupitrine. It is a neuronal potassium channel opener being developed as a first-in-class antiepileptic drug (AED) and is currently being studied in Phase 3 trials as an adjunctive treatment for partial-onset seizures in adult patients with refractory epilepsy....
Approved
Investigational
Matched Description: … is a neuronal potassium channel opener being developed as a first-in-class antiepileptic drug (AED) and
Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment of patients with unresectable or...
Approved
Investigational
Matched Description: … Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated ... It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment of ... protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Tyrothricin is an antibiotic peptide complex produced and extracted from the aerobic Gram-positive bacillus Brevibacillus parabrevis [L4019, L4021, A32851] which was previously categorized as Bacillus brevis and Bacillus aneurinolyticus . This complex is a mixture comprised of 60% tyrocidine cationic cyclic decapeptides (consisting largely of the six predominant tyrocidines, TrcA/A1,...
Approved
Matched Description: … Tyrothricin is an antibiotic peptide complex produced and extracted from the aerobic Gram-positive bacillus ... Brevibacillus parabrevis [L4019, L4021, A32851] which was previously categorized as Bacillus brevis and ... other more minor contributors) and 40% neutral linear gramicidins (where valine-gramicidin A is often …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Sevelamer is a phosphate binding drug used to prevent hyperphosphataemia in patients with chronic renal failure. It is marketed by Genzyme under the trade name Renagel.
Approved
Matched Categories: … Drugs for Treatment of Hyperkalemia and Hyperphosphatemia …
Nomifensine, formerly marketed as Merital capsules, was associated with an increased incidence of hemolytic anemia. The approved application holder removed Merital capsules from the market on January 23, 1986. FDA published a notice of its determination that Merital capsules were removed from the market for safety reasons (see the Federal...
Approved
Withdrawn
Matched Description: … Also withdrawn from the Canadian and UK markets. …
An alkaloid ester extracted from the leaves of plants including coca. It is a local anesthetic and vasoconstrictor and is clinically used for that purpose, particularly in the eye, ear, nose, and throat. It also has powerful central nervous system effects similar to the amphetamines and is a drug of...
Approved
Illicit
Matched Description: … the eye, ear, nose, and throat. ... It is a local anesthetic and vasoconstrictor and is clinically used for that purpose, particularly in ... It also has powerful central nervous system effects similar to the amphetamines and is a drug of abuse …
Matched Categories: … Analgesics and Anesthetics …
Mitapivat is a novel, first-in-class pyruvate kinase activator. It works to increase the activity of erythrocyte pyruvate kinase, a key enzyme involved in the survival of red blood cells. Defects in the pyruvate kinase enzyme in various red blood cells disorders lead to the lack of energy production for red...
Approved
Investigational
Matched Description: … alpha- and beta-thalassemia. ... other hereditary red blood cell disorders associated with hemolytic anemia, such as sickle cell disease and
Matched Categories: … Blood and Blood Forming Organs ... Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics …
Isradipine belongs to the dihydropyridine (DHP) class of calcium channel blockers (CCBs), the most widely used class of CCBs. It is structurally related to felodipine, nifedipine, and nimodipine and is the most potent calcium-channel blocking agent of the DHP class. Isradipine binds to calcium channels with high affinity and specificity...
Approved
Investigational
Matched Description: … Isradipine binds to calcium channels with high affinity and specificity and inhibits calcium flux into ... It is structurally related to felodipine, nifedipine, and nimodipine and is the most potent calcium-channel ... cardiac and arterial smooth muscle cells. …
Matched Categories: … Calcium-Regulating Hormones and Agents …
Remestemcel-L is a third-party, off-the-shelf suspension of ex-vivo cultured adult human mesenchymal stem cells intended for intravenous infusion. The mesenchymal stem cells are derived from the bone marrow of unrelated and human leukocyte antigen (HLA)–unmatched healthy adult donors and have the ability to differentiate into different tissue cells. It was...
Approved
Investigational
Matched Description: … cytokines and growth factors to promote tissue repair [A31818]. ... The mesenchymal stem cells are derived from the bone marrow of unrelated and human leukocyte antigen ... (HLA)–unmatched healthy adult donors and have the ability to differentiate into different tissue cells …
Durlobactam is a diazabicyclooctane non-beta-lactam, beta-lactamase inhibitor. It is typically given in combination with sulbactam to protect it from degradation by certain serine-beta-lactamases. The combination product of durlobactam and sulbactam was first approved by the FDA in May 2023. It is used to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial...
Approved
Investigational
Matched Description: … [L47336] The combination product of durlobactam and sulbactam was first approved by the FDA in May 2023 ... [A263306] It is used to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial …
Disorders such as schizophrenia and bipolar disorder can significantly impair mood, cognition, and behavior. These mental illnesses can often be accompanied by comorbidities such as depression and substance abuse, and can significantly impact the quality of life of patients and caregivers. Luckily, several treatment options for psychotic disorders have been...
Approved
Matched Description: … abuse, and can significantly impact the quality of life of patients and caregivers. ... Disorders such as schizophrenia and bipolar disorder can significantly impair mood, cognition, and behavior ... [A180748] It can effectively reduce the rate and time of relapses in schizophrenia, and can be used to …
Rupatadine is a dual histamine H1 receptor and platelet activating factor receptor antagonist that is used for symptomatic relief in seasonal and perennial rhinitis as well as chronic spontaneous urticaria. It was approved for marketing in Canada under the tradename Rupall and comes in tablet formulation for adult use and...
Approved
Matched Description: … adult use and liquid formulation for pediatric use. ... Rupatadine is a dual histamine H1 receptor and platelet activating factor receptor antagonist that is ... used for symptomatic relief in seasonal and perennial rhinitis as well as chronic spontaneous urticaria …
A nitrogen mustard alkylating agent used as antineoplastic agent for the treatment of various malignant and nonmalignant diseases. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed)
Approved
Matched Description: … nitrogen mustard alkylating agent used as antineoplastic agent for the treatment of various malignant and
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Iron sucrose (sucroferric oxyhydroxide or iron saccharate) is used as a source of iron in patients with iron deficiency anemia with chronic kidney disease (CKD), including those who are undergoing dialysis (hemodialysis or peritoneal) and those who do not require dialysis. Due to less side effects than iron dextran, iron...
Approved
Matched Description: … chronic kidney disease (CKD), including those who are undergoing dialysis (hemodialysis or peritoneal) and
Matched Categories: … Drugs for Treatment of Hyperkalemia and Hyperphosphatemia …
Golodirsen is a morpholino antisense oligomer designed to treat about 8% of patients with Duchenne Muscular Dystrophy (DMD). This is an X-linked condition leading to progressive muscle degeneration that begins in early childhood, rendering many patients wheelchair-bound by age 12. Often, patients succumb to this condition by age 30 or...
Approved
Matched Description: … [L10773] Golodirsen was developed by Sarepta Therapeutics and granted accelerated FDA approval on ... Often, patients succumb to this condition by age 30 or younger due to cardiac and respiratory complications …
Matched Categories: … Nucleic Acids, Nucleotides, and Nucleosides …
Haloperidol is a high potency first-generation (typical) antipsychotic and one of the most frequently used antipsychotic medications used worldwide. While haloperidol has demonstrated pharmacologic activity at a number of receptors in the brain, it exerts its antipsychotic effect through its strong antagonism of the dopamine receptor (mainly D2), particularly within...
Approved
Matched Description: … Haloperidol is a high potency first-generation (typical) antipsychotic and one of the most frequently ... through its strong antagonism of the dopamine receptor (mainly D2), particularly within the mesolimbic and ... [F4645] It is also used off-label for the management of chorea associated with Huntington's disease and
Fondaparinux (Arixtra) is a synthetic anticoagulant agent consisting of five monomeric sugar units and a O-methyl group at the reducing end of the molecule. It is structurally similar to polymeric glycosaminoglycan heparin and heparan sulfate (HS) when they are cleaved into monomeric units. The monomeric sequence in heparin and HS...
Approved
Investigational
Matched Description: … Fondaparinux (Arixtra) is a synthetic anticoagulant agent consisting of five monomeric sugar units and ... It is structurally similar to polymeric glycosaminoglycan heparin and heparan sulfate (HS) when they ... infarction (NSTEMI); and in the management of ST segment elevation myocardial infarction (STEMI). …
Matched Categories: … Blood and Blood Forming Organs …
Displaying drugs 901 - 925 of 14506 in total